Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy

Trial Profile

An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Apr 2019

At a glance

  • Drugs Nusinersen (Primary)
  • Indications Spinal muscular atrophy
  • Focus Adverse reactions
  • Acronyms SMNRx-CS2
  • Sponsors Biogen; Ionis Pharmaceuticals; Isis Pharmaceuticals
  • Most Recent Events

    • 24 Apr 2019 Long-term results assessing Nusinersen in later-onset spinal muscular atrophy in ISIS-396443-CS2 and ISIS-396443-CS12 studies, published in the Neurology
    • 09 Mar 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 10 Oct 2014 Interim results published in Isis Pharmaceuticals media release, and presented at the 19th International World Muscle Society (WMS) Congress, according to the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top